From: Evaluation of new and old biomarkers in dogs with degenerative mitral valve disease
Parameters | Control n = 21 | Stage B1 n = 41 | Stage B2 n = 9 | Stage C n = 14 |
---|---|---|---|---|
Demographics | ||||
  Breed (Mixed breed/Dachshund/CKCS/Beagle/Others) | (3/5/0/2/11) | (14/7/3/3/14) | (0/3/0/0/6) | (4/1/1/0/8) |
  ªAge (years) | 8.7 (± 2.3) | 10.8 (± 2.5)* | 11.1 (± 2.6) | 12.5 (± 2.6)* |
8.3 (7.8–10.7) | 11.2 (9.8–12.8) | 10.7 (10.5–12) | 12.7 (11.8–13.4) | |
  ªWeight (kg) | 9.3 (± 4.7) | 12.5 (± 6.4) | 12.8 (± 7.2) | 9.2 (± 5.2) |
7.8 (6–10) | 11 (8–16.6) | 9.8 (7.9–19.5) | 7.5 (6.4–11.1) | |
  Sex (f/fs/m/mn) | (6/4/2/9) | (2/18/6/15) | (3/1/3/2) | (0/7/5/2) |
Laboratory variables | ||||
  ªBUN (mg/dL) | 38.7 (± 17.9)*** | 35 (± 11.3)*** | 49.9 (± 26.7) | 58.9 (± 58.9) |
 | 34 (28.5–39.5) | 33 (26.5–44) | 37 (26–73) | 55.5 (37–76) |
  ªCREA (mg/dL) | 0.78 (± 0.18) | 0.79 (± 0.21) | 0.84 (± 0.37) | 0.79 (± 0.2) |
 | 0.71 (0.66–0.86) | 0.79 (0.65–0.91) | 0.97 (0.59–1.02) | 0.77 (0.66–0.94) |
Echocardiographic measurements | ||||
  ªLA/Ao | 1.24 (± 0.18) | 1.39 (± 0.22)* | 2.14 (± 0.36)*/** | 2.31 (± 0.57)*/** |
1.23 (1.12–1.32) | 1.42 (1.25–1.57) | 2.04 (1.89–2.45) | 2.22 (1.79–2.69) | |
  ªLVIDDn | 1.49 (± 0.15) | 1.6 (± 0.21) | 1.88 (± 0.26)*/** | 2.04 (± 0.32)*/** |
1.48 (1.39–1.58) | 1.57 (1.45–1.74) | 1.97 (1.77–2.02) | 1.99 (1.76–2.43) | |
  Reflux (0/1/2/3) | (21/0/0/0) | (0/23/13/5) | (0/1/2/6) | (0/0/2/12) |
Heart medicationb | ||||
  ACEI (yes/no) | (0/21) | (2/40) | (4/8) | (6/10) |
  Pimobendan (yes/no) | (0/21) | (4/37) | (6/3) | (7/5) |
  Loop Diuretics (yes/no) | (0/21) | (0/41) | (0/9) | (3/11) |
  Spironolactone (yes/no) | (0/21) | (1/40) | (3/6) | (3/11) |